Becker Muscular Dystrophy-Pipeline Review, H2 2018: Ken Research

0


Becker Muscular Dystrophy, or as commonly called as MD or BMD, is a genetic disorder that weakens the muscles and makes them smaller. The most common type is Duchenne Muscular Dystrophy, but BMD causes less severe problems than that. Symptoms of BMD can be seen when kids are around 10-13 years old and their walking problems become apparent around 15-16 years of age. BMD rarely causes any health problems until muscle weakness occurs in the pelvic region and hips. Kids with BMD find difficulty with sports, climbing stairs, lifting weights and load. Their calf muscles look bigger than the usual. Becker MD affects even heart muscles, which advances faster than in any other muscles. Becker MD progresses with age; its symptoms worsen slowly as age progresses. As far as respiration is concerned, breathing muscles are strong enough to avoid any ventilators or mechanical breathing. The cause for Becker MD is due to the protein made by muscle cells, dystrophy in which does not function normally as it should. Usually, the body is capable of repairing these cells but in Becker MD, the cells die instead of being replaced. In the place of the old Becker MD cells, fat and scar tissues get accumulated. Becker MD mostly affects children, especially boys with profound weakness in their limbs. Girls also have symptoms but is less severe than in boys.

Like in Duchenne muscular dystrophy, Becker MD is caused by mutations in the same gene. But the symptoms are milder because of the type of mutation. Finding and characterizing the type of mutation has brought deeper and important insights into understanding the underlying biology of both these conditions. This fact has been prima facie in the development of therapeutic approaches.

Pipeline Review is an online portal that provides R&D new and online shop for reports about research & development in the biopharmaceutical industry. Ken Research’s Becker Muscular Dystrophy-Pipeline Review, H2 2018 gives a snapshot of the therapeutic landscape of the disorder. The report covers therapeutic reviews based on their companies and research institutions based on their information derived from industry-specific sources. It provides descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The companies involved in the therapeutic development of Becker Muscular Dystrophy are Catabasis Pharmaceuticals Inc, Italfarmaco SpA, Milo Biotechnology LLC, PTC Therapeutics Inc, and ReveraGen Bio Pharma Inc. The report will help in procuring important information on competitors and their analysis to formulate R&D strategies to develop tactical initiatives in the target demographic.

To know more, click on the link below:

Becker Muscular Dystrophy-Pipeline Review, H2 2018

Related reports:

Becker Muscular Dystrophy-Pipeline Review, H1 2017

Becker Muscular Dystrophy Global Clinical Trials Review, H2, 2016

Contact us:

Ken research

Ankur Gupta, head marketing & communications

sales@kenresearch.com

+91-9015378249

Share.

Comments are closed.